Vanflyta (quizartinib) - Daiichi Sankyo
tandutinib (MLN518) - Takeda
crenolanib (ARO-002) - AROG
https://ash.confex.com/ash/2024/webprogram/Paper201449.html
 
Melissa Zwick1,2; Bastian Zinkel1,2; Corinna Spohr3; Tamina Rückert1; Sebastian Halbach3,4; Khalid Shoumariyeh, MD1,4; Lukas M. Braun1,2; Annika Nelde5,6; Melanie Maerklin6,7; Samuel J. Holzmayer6,7; Sandra Duquesne1; Alexandra Emilia Schlaak8; Patricia Otto-Mora8; Bertram Bengsch8,9,10,11; Marcel Schiff1; Sandra Kissel1; Marie Follo1; Heidi Altmann12, Désirée Kunadt12; Anna Lena Illert1,4,13,14; Juliane S. Walz, MD5,6,7,15; Gerd Walz9,16,17; Justus Duyster, MD1,18; Johannes Schetelig, MD, MSc11,12; Tilman Brummer, PhD3,4,9,19; Robert Zeiser, MD1,4,9,17; Natalie Koehler1,17
 
Nov 6, 2024
 
Prev Next